Literature DB >> 24201121

Monoclonality and cytogenetic abnormalities in hyaline vascular Castleman disease.

Kung-Chao Chang1, Yu-Chu Wang2, Liang-Yi Hung2, Wan-Ting Huang3, Jen-Hui Tsou2, Dan M Jones4, Hsiang-Lin Song1, Yu-Min Yeh5, Lin-Yuan Kao1, L Jeffrey Medeiros6.   

Abstract

Hyaline vascular Castleman disease is traditionally regarded as a reactive hyperplastic process. Occasional cases, however, have been reported with cytogenetic anomalies bringing this concept into question. In this study, we used conventional and methylation-specific polymerase chain reaction methods to assess the human androgen receptor α (HUMARA) gene in 29 female patients with hyaline vascular Castleman disease and compared the results with three cases of plasma cell Castleman disease and 20 cases of age-matched lymphoid hyperplasia. We also assessed for immunoglobulin gene and T-cell receptor gene rearrangements, and conventional cytogenetic analysis was performed in three cases of hyaline vascular Castleman disease. In cases with informative results, conventional and methylation-specific human androgen receptor α gene analyses yielded a monoclonal pattern in 10 of 19 (53%) and 17 of 23 (74%) cases of hyaline vascular Castleman disease, respectively. A monoclonal pattern was also detected in three cases of plasma cell Castleman disease but not in cases of lymphoid hyperplasia. The frequency of monoclonality was higher for lesions >5 cm in size (100%) and for the stromal-rich variant (91%). Cytogenetic abnormalities in stromal cells were revealed in two cases of hyaline vascular Castleman disease and no cases showed monoclonal immunoglobulin or T-cell receptor gene rearrangements. Follow-up data showed persistent disease in 4 of 23 (17%) patients. We conclude that hyaline vascular Castleman disease is often a monoclonal proliferation, most likely of lymph node stromal cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24201121     DOI: 10.1038/modpathol.2013.202

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  18 in total

Review 1.  Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Analysis of clinical characteristics and prognosis factors of 71 cases with HIV-negative Castleman's disease: hypoproteinemia is an unfavorable prognostic factor which should be treated appropriately.

Authors:  Xuan Lan; Zhaoming Li; Mingzhi Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-07       Impact factor: 4.553

Review 3.  Multicentric Castleman disease: Where are we now?

Authors:  Hao-Wei Wang; Stefania Pittaluga; Elaine S Jaffe
Journal:  Semin Diagn Pathol       Date:  2016-05-16       Impact factor: 3.464

4.  Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas.

Authors:  Alexandra Nagy; Aparna Bhaduri; Nahid Shahmarvand; Jahanbanoo Shahryari; James L Zehnder; Roger A Warnke; Tariq Mughal; Siraj Ali; Robert S Ohgami
Journal:  Blood Adv       Date:  2018-03-13

Review 5.  Castleman disease.

Authors:  Antonino Carbone; Margaret Borok; Blossom Damania; Annunziata Gloghini; Mark N Polizzotto; Raj K Jayanthan; David C Fajgenbaum; Mark Bower
Journal:  Nat Rev Dis Primers       Date:  2021-11-25       Impact factor: 65.038

6.  Transcriptome and unique cytokine microenvironment of Castleman disease.

Authors:  Anna Wing; Jason Xu; Wenzhao Meng; Aaron M Rosenfeld; Elizabeth Y Li; Gerald Wertheim; Michele Paessler; Adam Bagg; Dale Frank; Kai Tan; David T Teachey; Megan S Lim; Eline Luning Prak; David C Fajgenbaum; Vinodh Pillai
Journal:  Mod Pathol       Date:  2021-10-22       Impact factor: 8.209

Review 7.  Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum
Journal:  Blood       Date:  2018-11-29       Impact factor: 22.113

8.  International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.

Authors:  Frits van Rhee; Eric Oksenhendler; Gordan Srkalovic; Peter Voorhees; Megan Lim; Angela Dispenzieri; Makoto Ide; Sophia Parente; Stephen Schey; Matthew Streetly; Raymond Wong; David Wu; Ivan Maillard; Joshua Brandstadter; Nikhil Munshi; Wilbur Bowne; Kojo S Elenitoba-Johnson; Alexander Fössa; Mary Jo Lechowicz; Shanmuganathan Chandrakasan; Sheila K Pierson; Amy Greenway; Sunita Nasta; Kazuyuki Yoshizaki; Razelle Kurzrock; Thomas S Uldrick; Corey Casper; Amy Chadburn; David C Fajgenbaum
Journal:  Blood Adv       Date:  2020-12-08

9.  Tumor suppressors TSC1 and TSC2 differentially modulate actin cytoskeleton and motility of mouse embryonic fibroblasts.

Authors:  Elena A Goncharova; Melane L James; Tatiana V Kudryashova; Dmitry A Goncharov; Vera P Krymskaya
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

Review 10.  Laparoscopic treatment of abdominal unicentric castleman's disease: a case report and literature review.

Authors:  Umberto Bracale; Francesco Pacelli; Marco Milone; Umberto Marcello Bracale; Maurizio Sodo; Giovanni Merola; Teresa Troiani; Enrico Di Salvo
Journal:  BMC Surg       Date:  2017-04-12       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.